Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

被引:195
作者
Estey, Elihu
de Lima, Marcos
Tibes, Raoul
Pierce, Sherry
Kantarjian, Hagop
Champlin, Richard
Giralt, Sergio
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
关键词
D O I
10.1182/blood-2006-05-021907
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To prospectively assess the applicability of reduced-intensity conditioning hematopoletic stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myelold leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first complete remission (CR1). Ninety-nine of 259 patients entered CR. Fifty-three of the 99 were seen by the Transplant Service with the remainder not seen because of illness, lack/unavailability of siblings, refusal, or, primarily, unclear reasons (21 patients). A donor was identified for 26 patients (21 sibling, 5 unrelated) with RIC-HSCT performed in 14 (13 sibling). Results in consulted patients suggested that 50% or fewer of the 85 patients who did not undergo transplantation were potential transplant candidates. We attempted to find one or more chemotherapy pair-mates for each patient who underwent transplantation based on cytogenetics, age, and a relapse-free survival (RFS) time that was more than or equal to the time from CR1 to RIC-HSCT in the patient who under-went transplantation. Thirty-two of the 39 matches favored (longer RFS) RIC-HSCT and 7, chemotherapy. The probability that the corresponding beta distribution was different than expected (i.e, that RIC-HSCT was superior) was 0.99 (P =.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability.
引用
收藏
页码:1395 / 1400
页数:6
相关论文
共 25 条
[11]   The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial [J].
Grimwade, D ;
Walker, H ;
Harrison, G ;
Oliver, F ;
Chatters, S ;
Harrison, CJ ;
Wheatley, K ;
Burnett, AK ;
Goldstone, AH .
BLOOD, 2001, 98 (05) :1312-1320
[12]   Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning [J].
Ho, AYL ;
Pagliuca, A ;
Kenyon, M ;
Parker, JE ;
Mijovic, A ;
Devereux, S ;
Mufti, GJ .
BLOOD, 2004, 104 (06) :1616-1623
[13]   The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA [J].
Keating, S ;
de Witte, T ;
Suciu, S ;
Willemze, R ;
Hayat, M ;
Labar, B ;
Resegotti, L ;
Ferrini, PR ;
Caronia, F ;
Dardenne, M ;
Solbu, G ;
Petti, MC ;
Vegna, ML ;
Mandelli, F ;
Zittoun, RA .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (05) :1344-1353
[14]   The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia:: a donor vs no donor comparison [J].
Mohty, M ;
de Lavallade, H ;
Ladaique, P ;
Faucher, C ;
Vey, N ;
Coso, D ;
Stoppa, AM ;
Gastaut, JA ;
Blaise, D .
LEUKEMIA, 2005, 19 (06) :916-920
[15]   Cytogenetics in acute leukemia [J].
Mrózek, K ;
Heerema, NA ;
Bloomfield, CD .
BLOOD REVIEWS, 2004, 18 (02) :115-136
[16]  
Niederwieser DW, 2004, BLOOD, V104, p840A
[17]   Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia:: disease status by marrow blasts is the strongest prognostic factor [J].
Sayer, HG ;
Kröger, M ;
Beyer, J ;
Kiehl, M ;
Klein, SA ;
Schaefer-Eckart, K ;
Schwerdtfeger, R ;
Siegert, W ;
Runde, V ;
Theuser, C ;
Martin, H ;
Schetelig, J ;
Beelen, DW ;
Fauser, A ;
Kienast, J ;
Höffken, K ;
Ehninger, G ;
Bornhäuser, M .
BONE MARROW TRANSPLANTATION, 2003, 31 (12) :1089-1095
[18]   Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation [J].
Schmid, Christoph ;
Schleuning, Michael ;
Schwerdtfeger, Rainer ;
Hertenstein, Bernd ;
Mischak-Weissinger, Eva ;
Bunjes, Donald ;
v. Harsdorf, Stephanie ;
Scheid, Christoph ;
Holtick, Udo ;
Greinix, Hildegard ;
Keil, Felix ;
Schneider, Barbara ;
Sandherr, Michael ;
Bug, Gesine ;
Tischer, Johanna ;
Ledderose, Georg ;
Hallek, Michael ;
Hiddemann, Wolfgang ;
Kolb, Hans-Jochem .
BLOOD, 2006, 108 (03) :1092-1099
[19]   Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies:: older age is no longer a contraindication when using reduced intensity conditioning [J].
Shimoni, A ;
Kröger, N ;
Zabelina, T ;
Ayuk, F ;
Hardan, I ;
Yeshurun, M ;
Shem-Tov, N ;
Avigdor, A ;
Ben-Bassat, I ;
Zander, AR ;
Nagler, A .
LEUKEMIA, 2005, 19 (01) :7-12
[20]   Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study [J].
Slovak, ML ;
Kopecky, KJ ;
Cassileth, PA ;
Harrington, DH ;
Theil, KS ;
Mohamed, A ;
Paietta, E ;
Willman, CL ;
Head, DR ;
Rowe, JM ;
Forman, SJ ;
Appelbaum, FR .
BLOOD, 2000, 96 (13) :4075-4083